Shaily Engineering Plastics Limited has informed the Exchange about Transcript
SHAILY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shaily Engineering Plastics reported strong Q1 FY26 results with consolidated revenue of INR 247 crores, up 38% year-on-year, driven by the Pharma/Healthcare segment which surged 181% YoY to INR 77 crores. EBITDA nearly doubled to INR 70.4 crores with margins expanding 840 basis points to 28.5%, while PAT grew 136% YoY to INR 41.1 crores. The company has commenced commercial manufacturing of GLP-1 pens for semaglutide and is investing INR 125 crores in capex to scale pen capacity from the current 40-45 million units to 70-75 million units by early FY27, with 50-60% of the expanded capacity backed by customer commitments (including take-or-pay contracts) and management targeting full utilization by FY28. The Consumer segment grew 14% YoY, supported by new wins in mixed-material (steel + plastic) products and male accessories from a marquee FMCG customer. The company also reported 60-70% market share in semaglutide filings in Canada and is preparing to launch a next-generation GLP-1 device at CPHI Frankfurt in October targeting large innovator pharma.
This is a clear growth inflection quarter, with the GLP-1 pen business scaling rapidly and margins expanding sharply, which is positive for the stock. Investors should watch for execution on the pen capacity ramp-up, customer product launches, and approval timelines over the next few quarters as key catalysts.